Non Hodgkin Lymphoma

Oncology
14
Pipeline Programs
9
Companies
39
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
2
5
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 13 programs with unclassified modality

On Market (1)

Approved therapies currently available

GS
ZYDELIGApproved
idelalisib
Gilead Sciences
oral2014

Competitive Landscape

9 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
6 programs
2
1
3
1
AnakinraPhase 21 trial
ZYDELIG(Zydelig)Phase 21 trial
ZydeligPhase 2
MagrolimabPhase 1/2Monoclonal Antibody1 trial
TmCD19-IL18Phase 1
+1 more programs
Active Trials
NCT05989204Recruiting24Est. Oct 2041
NCT02953509Terminated178Est. Mar 2024
NCT04150913Completed15Est. Oct 2024
+1 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
enzastaurinPhase 31 trial
Active Trials
NCT00332202Completed758Est. Jul 2013
Novartis
NovartisBASEL, Switzerland
1 program
1
CTL019Phase 21 trial
Active Trials
NCT04161118Terminated3Est. Feb 2023
Sanofi
SanofiPARIS, France
1 program
1
Fludarabine PhosphatePhase 24 trials
Active Trials
NCT00311129Completed41Est. Jul 2007
NCT00185445Completed62Est. Oct 2006
NCT00688883Completed52Est. Aug 2004
+1 more trials
ImmunityBio
ImmunityBioSAN DIEGO, CA
1 program
1
avelumabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT03169790Withdrawn0Est. Dec 2021
Secura Bio
Secura BioNV - Las Vegas
1 program
1
BMS-986345Phase 11 trial
Active Trials
NCT05065866CompletedEst. Apr 2024
H
HutchmedChina - Hong Kong
1 program
1
HMPL-523Phase 11 trial
Active Trials
NCT03779113Terminated69Est. Feb 2025
TG Therapeutics
TG TherapeuticsNEW YORK, NY
1 program
1
TG-1701Phase 11 trial
Active Trials
NCT03671590Terminated172Est. May 2024
Amgen
AmgenTHOUSAND OAKS, CA
2 programs
On-body injectorN/A1 trial
PegfilgrastimN/A5 trials
Active Trials
NCT03619993Completed404Est. Sep 2019
NCT00117455Completed
NCT00124111Completed
+3 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
AmgenPegfilgrastim
AmgenPegfilgrastim
SanofiFludarabine Phosphate
Eli Lilly and Companyenzastaurin
AmgenPegfilgrastim
AmgenPegfilgrastim
NovartisCTL019
Gilead SciencesAnakinra
AmgenPegfilgrastim
Gilead SciencesZydelig
AmgenPegfilgrastim
AmgenPegfilgrastim
AmgenPegfilgrastim
AmgenPegfilgrastim
AmgenPegfilgrastim

Showing 15 of 37 trials with date data

Clinical Trials (39)

Total enrollment: 7,642 patients across 39 trials

NCT00125723AmgenPegfilgrastim

FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy

Start: May 2004Est. completion: Dec 20052,252 patients
Phase 4Completed
NCT00115206AmgenPegfilgrastim

Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy

Start: Jul 2002Est. completion: Jul 2004
Phase 4Completed
NCT00220311SanofiFludarabine Phosphate

A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia

Start: Nov 2000Est. completion: Sep 200510 patients
Phase 4Completed
NCT00332202Eli Lilly and Companyenzastaurin

PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

Start: Jun 2006Est. completion: Jul 2013758 patients
Phase 3Completed
NCT00117910AmgenPegfilgrastim

Treatment for Elderly Patients With High Risk Breast Cancer

Start: Oct 2002Est. completion: May 2004
Phase 3Completed
NCT00035594AmgenPegfilgrastim

Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy

Start: Feb 2002Est. completion: Jun 2004928 patients
Phase 3Completed
NCT00117455AmgenPegfilgrastim

A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma

Phase 2Completed
NCT00124111AmgenPegfilgrastim

A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer

Phase 2Completed
NCT04161118NovartisCTL019

TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Start: May 2021Est. completion: Feb 20233 patients
Phase 2Terminated
NCT04150913Gilead SciencesAnakinra

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Start: Oct 2020Est. completion: Oct 202415 patients
Phase 2Completed
NCT03571633AmgenPegfilgrastim

Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer

Start: Aug 2018Est. completion: Sep 202790 patients
Phase 2Active Not Recruiting
NCT03133221Gilead SciencesZydelig

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

Start: Oct 2017Est. completion: Sep 202417 patients
Phase 2Completed
NCT01752907AmgenPegfilgrastim

Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim

Start: Jan 2013Est. completion: Dec 2014304 patients
Phase 2Completed
NCT01712009AmgenPegfilgrastim

NOLAN: Naproxen or Loratadine and Neulasta

Start: Nov 2012Est. completion: Mar 2015600 patients
Phase 2Completed
NCT01671319AmgenPegfilgrastim

Dose Dense TC + Pegfilgrastim Support for Breast Cancer

Start: Jun 2011Est. completion: Apr 201342 patients
Phase 2Completed
NCT01313884AmgenPegfilgrastim

Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma

Start: May 2011Est. completion: Jul 20143 patients
Phase 2Terminated
NCT00794261AmgenPegfilgrastim

Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma

Start: Sep 2008Est. completion: Jun 2010150 patients
Phase 2Completed
NCT00695370AmgenPegfilgrastim

Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children

Start: Jan 2006Est. completion: Jan 200830 patients
Phase 2Terminated
NCT00311129SanofiFludarabine Phosphate

Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL

Start: Dec 2005Est. completion: Jul 200741 patients
Phase 2Completed
NCT00185445SanofiFludarabine Phosphate

Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL

Start: Jun 2004Est. completion: Oct 200662 patients
Phase 2Completed
NCT00067639AmgenPegfilgrastim

Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma

Start: Dec 2003Est. completion: Apr 200750 patients
Phase 2Completed
NCT00280787AmgenPegfilgrastim

Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim

Start: Nov 2003Est. completion: Oct 201024 patients
Phase 2Completed
NCT00066092AmgenPegfilgrastim

Pegfilgrastim PBPC Mobilization Study

Start: Apr 2003Est. completion: Oct 200441 patients
Phase 2Completed
NCT00193479AmgenPegfilgrastim

Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma

Start: Apr 2003Est. completion: Feb 201051 patients
Phase 2Completed
NCT00114764AmgenPegfilgrastim

Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)

Start: Mar 2003Est. completion: Aug 200484 patients
Phase 2Completed
NCT00115193AmgenPegfilgrastim

Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma

Start: Feb 2003Est. completion: Aug 200577 patients
Phase 2Completed
NCT00688883SanofiFludarabine Phosphate

Fludara (Oral) Phase II Study for Indolent Lymphoma

Start: Feb 2003Est. completion: Aug 200452 patients
Phase 2Completed
NCT00117897AmgenPegfilgrastim

Treatment for Subjects With Non-Hodgkin's Lymphoma

Start: Jul 2002Est. completion: Feb 2004
Phase 2Completed
NCT00035620AmgenPegfilgrastim

Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy

Start: Apr 2000Est. completion: Apr 200744 patients
Phase 2Completed
NCT03169790ImmunityBioavelumab

QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

Start: Dec 2017Est. completion: Dec 20210
Phase 1/2Withdrawn
NCT02953509Gilead SciencesMagrolimab

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Start: Nov 2016Est. completion: Mar 2024178 patients
Phase 1/2Terminated
NCT05989204Gilead SciencesTmCD19-IL18

TmCD19-IL18 in CD19+ Cancers

Start: Nov 2023Est. completion: Oct 204124 patients
Phase 1Recruiting
NCT05065866Secura BioBMS-986345

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Start: Nov 2021Est. completion: Apr 2024
Phase 1Completed
NCT03779113HutchmedHMPL-523

An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

Start: Sep 2019Est. completion: Feb 202569 patients
Phase 1Terminated
NCT03671590TG TherapeuticsTG-1701

Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies

Start: Sep 2018Est. completion: May 2024172 patients
Phase 1Terminated
NCT03619993AmgenOn-body injector

Patient Preference for Pegfilgrastim (Neulasta®) Application Forms

Start: Jun 2018Est. completion: Sep 2019404 patients
N/ACompleted
NCT02178475AmgenPegfilgrastim

Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy

Start: Jul 2014Est. completion: Oct 2016943 patients
N/ACompleted
NCT01541072AmgenPegfilgrastim

Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation

Start: Feb 2012Est. completion: Sep 201434 patients
N/ATerminated
NCT00094822AmgenPegfilgrastim

Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC)

Start: Jul 2003Est. completion: Feb 200690 patients
N/ACompleted

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
5h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
7h ago

Executive Medical Director, Oncology Early Development

AbbVie
Florham Park, NJ
8h ago

Executive Medical Director, Oncology Early Development

AbbVie
South San Francisco, CA
8h ago

Executive Medical Director, Oncology Early Development

AbbVie
North Chicago, IL
8h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 7,642 patients
9 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)